Last reviewed · How we verify
ENALAPRILAT ANHYDROUS
At a glance
| Generic name | ENALAPRILAT ANHYDROUS |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1988 |
Approved indications
Common side effects
Key clinical trials
- Genetic Determinants of ACEI Prodrug Activation (PHASE4)
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Postpartum Evaluation of Nifedipine and Enalapril for Hypertension (PHASE4)
- A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury. (NA)
- Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars (PHASE2, PHASE3)
- Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition (PHASE4)
- An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) (PHASE3)
- COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENALAPRILAT ANHYDROUS CI brief — competitive landscape report
- ENALAPRILAT ANHYDROUS updates RSS · CI watch RSS